When Sunshine Biopharma, a development stage pharmaceutical company focused on cancer treatments, recently announced successful test results for its lead compound, Adva-27a, it represented one of several important milestones being met on the drug’s anticipated fast-track path to approval as a vital weapon in fighting particular forms of aggressive cancers.
The latest study measured the ability of Adva-27a to inhibit the activity of Topoisomerase II (Top2) cancer growth enzyme, and results showed that the new drug is an excellent inhibitor, requiring a concentration of only 13.7 micromolar Adva-27a to inhibit 50% of the enzyme’s activity. Topoisomerase II is overproduced in aggressive cancer cells, giving them the ability to grow rapidly, and has been implicated in breast, prostate, colon, lung, stomach, and ovarian cancer.
The success of Adva-27a is especially important, since there are currently very limited options for Top2 positive patients. With no other effective therapy for Top2, Adva-27a is likely to be granted fast-track designation, especially since it could help terminally ill patients, further enhancing the drug’s unique potential in the marketplace:
• Adva-27a will be the only Topoisomerase II inhibitor on the market
• Adva-27a can be taken orally.
• Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
• Adva-27a has an excellent clearance time, reducing toxicity risks, and clearance is independent of Cytochrome P450, making it less likely to produce toxic intermediates.
• Adva-27a’s initial indication will be multi-drug resistant breast cancer.
• Adva-27a has been shown to be 16 times more effective at killing multi-drug resistant breast cancer cells than Etoposide, the most commonly used drug.
• Adva-27a can be used to treat other Top2 Positive Cancer Types (Prostate, Colon, Lung, Stomach, Ovarian).
Sunshine Biopharma is planning to expand its product line through acquisitions and/or in-licensing, as well as in-house research and development.
For additional information, visit the company’s websites at www.SunshineBiopharma.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment